Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Expected to Announce Earnings of -$1.73 Per Share

Brokerages predict that Ultragenyx Pharmaceutical Inc. (NASDAQ:RAREGet Rating) will announce ($1.73) earnings per share for the current quarter, Zacks Investment Research reports. Nine analysts have issued estimates for Ultragenyx Pharmaceutical’s earnings. The highest EPS estimate is ($1.46) and the lowest is ($2.21). Ultragenyx Pharmaceutical reported earnings of ($2.03) per share in the same quarter last year, which indicates a positive year-over-year growth rate of 14.8%. The firm is scheduled to report its next earnings results on Monday, January 1st.

According to Zacks, analysts expect that Ultragenyx Pharmaceutical will report full-year earnings of ($6.57) per share for the current fiscal year, with EPS estimates ranging from ($7.92) to ($4.74). For the next fiscal year, analysts anticipate that the firm will post earnings of ($4.79) per share, with EPS estimates ranging from ($6.16) to ($2.93). Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side analysts that that provide coverage for Ultragenyx Pharmaceutical.

Ultragenyx Pharmaceutical (NASDAQ:RAREGet Rating) last posted its quarterly earnings data on Thursday, February 10th. The biopharmaceutical company reported ($1.79) earnings per share for the quarter, missing the consensus estimate of ($1.32) by ($0.47). The firm had revenue of $83.39 million for the quarter, compared to analysts’ expectations of $83.68 million. Ultragenyx Pharmaceutical had a negative return on equity of 44.24% and a negative net margin of 129.20%. The company’s revenue for the quarter was down 8.9% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($1.34) earnings per share.

Several equities analysts have weighed in on the company. Credit Suisse Group raised Ultragenyx Pharmaceutical from a “neutral” rating to an “outperform” rating and lifted their target price for the company from $99.00 to $105.00 in a research note on Wednesday, March 16th. Zacks Investment Research raised shares of Ultragenyx Pharmaceutical from a “sell” rating to a “hold” rating and set a $75.00 price target on the stock in a research note on Tuesday, February 15th. StockNews.com initiated coverage on Ultragenyx Pharmaceutical in a research note on Thursday, March 31st. They issued a “hold” rating on the stock. Morgan Stanley cut their price target on Ultragenyx Pharmaceutical from $120.00 to $118.00 and set an “overweight” rating for the company in a research note on Friday, February 11th. Finally, JPMorgan Chase & Co. upgraded Ultragenyx Pharmaceutical from a “neutral” rating to an “overweight” rating and set a $132.00 price target for the company in a report on Friday, February 11th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and ten have issued a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $122.27.

Shares of RARE stock opened at $85.40 on Wednesday. Ultragenyx Pharmaceutical has a 1-year low of $61.21 and a 1-year high of $119.54. The stock’s fifty day simple moving average is $71.23 and its 200-day simple moving average is $76.69.

In other Ultragenyx Pharmaceutical news, insider John Richard Pinion sold 4,498 shares of Ultragenyx Pharmaceutical stock in a transaction on Tuesday, March 1st. The stock was sold at an average price of $66.62, for a total value of $299,656.76. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Thomas Richard Kassberg sold 10,281 shares of the stock in a transaction that occurred on Friday, March 11th. The shares were sold at an average price of $67.01, for a total transaction of $688,929.81. The disclosure for this sale can be found here. Insiders sold 24,289 shares of company stock worth $1,602,749 over the last quarter. 6.70% of the stock is currently owned by corporate insiders.

A number of hedge funds have recently modified their holdings of the business. Nordea Investment Management AB lifted its stake in Ultragenyx Pharmaceutical by 19.0% in the first quarter. Nordea Investment Management AB now owns 9,151 shares of the biopharmaceutical company’s stock valued at $660,000 after acquiring an additional 1,459 shares during the last quarter. Privium Fund Management UK Ltd acquired a new stake in shares of Ultragenyx Pharmaceutical in the fourth quarter valued at approximately $8,579,000. Norges Bank bought a new stake in shares of Ultragenyx Pharmaceutical during the 4th quarter valued at $52,268,000. Barclays PLC lifted its position in Ultragenyx Pharmaceutical by 396.9% during the fourth quarter. Barclays PLC now owns 23,430 shares of the biopharmaceutical company’s stock worth $1,970,000 after purchasing an additional 18,715 shares during the period. Finally, JustInvest LLC lifted its holdings in shares of Ultragenyx Pharmaceutical by 113.2% during the 4th quarter. JustInvest LLC now owns 13,086 shares of the biopharmaceutical company’s stock worth $1,100,000 after acquiring an additional 6,947 shares during the period. Hedge funds and other institutional investors own 97.52% of the company’s stock.

Ultragenyx Pharmaceutical Company Profile (Get Rating)

Ultragenyx Pharmaceutical, Inc is a biopharmaceutical company, engages in the identification, acquisition, development and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Its product includes Mepsevii and Crysvita. Mepsevii is an intravenous, which is used for the treatment of Mucopolysaccharidosis VII.

Featured Stories

Get a free copy of the Zacks research report on Ultragenyx Pharmaceutical (RARE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.